A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781
Age 18 +
Sex Both
Phase Phase 4
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and provide more effective options for managing the disease. Here are some key details about the study:
- The treatment involves a combination of different therapies, which may work together to enhance effectiveness.
- It targets a specific aspect of the disease, potentially leading to better management and control.
- The study includes patients who have previously received treatment, allowing researchers to assess the effectiveness of the new approach in those who may have limited options.
- Researchers are looking at how well the treatment works and what side effects may occur, providing valuable information for future therapies.
- This study is unique because it combines multiple treatment strategies, which could lead to improved outcomes compared to standard treatments.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
